Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Forum
  • Nora AI
  • About Us
    • Our Coverage
    • Team
Press release

BioStock Studio: Spago Nanomedical's CDO on the endometriosis study

Spago Nanomedical

First North-listed Spago Nanomedical has recently initiated a phase IIa study with the MRI contrast agent SpagoPix in endometriosis. Paul Hargreaves, Chief Development Officer, visited BioStock's studio and talked about the disease, the need for better diagnostics and the phase IIa study.

Watch the interview with Spago Nanomedical's CDO Paul Hargreaves at biostock.se:

https://www.biostock.se/en/2022/12/spago-nanomedicals-cdo-on-the-endometriosis-study/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • X (Twitter)
Get in touch
  • info@hcandersencapital.dk
  • Bredgade 23B, 2. sal
    1260 København K
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.